Johnson and Johnson's (NYSE:JNJ) Oncology drugs account for around 10% of the company's overall revenues and EBITDA. Oncology has been a key growth driver for J&J in the recent past, and we expect this trend to continue in the near term and beyond, primarily led by a ramp in sales of existing...
Johnson & Johnson's Oncology Segment Will Likely See Strong Growth In The Near Term
Forbes - 31 Aug 2018 17:18
Johnson and Johnson's (NYSE:JNJ) Oncology drugs account for around 10% of the company's overall revenues and EBITDA. Oncology has been a key growth driver for J&J in the recent past, and we expect this trend to continue in the near term and beyond, primarily led by a ramp in sales of existing...
Share this Article
Recommended